Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.
Secretory immunoglobulin A (IgA) antibodies (sIgA) directed against cholera toxin (CT) and surface components of Vibrio cholerae are associated with protection against cholera, but the relative importance of specific sIgAs in protection is unknown. A monoclonal IgA directed against the V. cholerae lipopolysaccharide (LPS), secreted into the intestines of neonatal mice bearing hybridoma tumors, was previously shown to provide protection against a lethal oral dose of 10(7) V. cholerae cells. We show here that a single oral dose of 5 to 50 micrograms of the monoclonal anti-LPS IgA, given within 2 h before V. cholerae challenge, protected neonatal mice against challenge. In contrast, an oral dose of 80 micrograms of monoclonal IgA directed against CT B subunit (CTB) failed to protect against V. cholerae challenge. A total of 80 micrograms of monoclonal anti-CTB IgA given orally protected neonatal mice from a lethal (5-micrograms) oral dose of CT. Secretion of the same anti-CTB IgA antibodies into the intestines of mice bearing IgA hybridoma backpack tumors, however, failed to protect against lethal oral doses of either CT (5 micrograms) or V. cholerae (10(7) cells). Furthermore, monoclonal anti-CTB IgA, either delivered orally or secreted onto mucosal surfaces in mice bearing hybridoma tumors, did not significantly enhance protection over that provided by oral anti-LPS IgA alone. These results demonstrate that anti-LPS sIgA is much more effective than anti-CT IgA in prevention of V. cholerae-induced diarrheal disease.
Apter
F M
FM
GI Cell Biology Laboratory, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Michetti
P
P
Winner
L S
LS
Mack
J A
JA
Mekalanos
J J
JJ
Neutra
M R
MR
D000284:Administration, Oral; D000818:Animals; D000831:Animals, Newborn; D000907:Antibodies, Bacterial / Q000008:administration & dosage / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D001422:Bacterial Adhesion / Q000276:immunology; D002771:Cholera / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D002772:Cholera Toxin / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000633:toxicity; D004848:Epithelium / Q000382:microbiology; D006825:Hybridomas / Q000276:immunology; D007070:Immunoglobulin A / Q000008:administration & dosage / Q000494:pharmacology; D007421:Intestine, Small / Q000382:microbiology; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000633:toxicity; D051379:Mice; D008807:Mice, Inbred BALB C; D014734:Vibrio cholerae / Q000276:immunology*
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D007070:Immunoglobulin A; D008070:Lipopolysaccharides; D002772:Cholera Toxin